The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial

Yi L, et al. · GeroScience

Blood NAD+ rose dose-dependently in all NMN arms (P<=0.001), six-minute walking distance improved modestly vs placebo, and no safety concerns emerged up to 900 mg/day; no joint outcomes were assessed.

Population

Healthy middle-aged adults, 60 days

Intervention

NMN 300, 600 or 900 mg/day orally for 60 days

Comparator

Placebo

Limitations

Sponsored by an NMN manufacturer (Abinopharm); soft functional endpoints; 60 days only; no joint or cartilage measures.